Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
Dr. Sklavos joins Arcellx with over 15 years of experience in biomedical and clinical research in academic, government and industry settings. Dr. Sklavos brings broad drug development expertise to Arcellx as a result of managing multiple complex projects and portfolios comprised of various drug modalities including monoclonal and bispecific antibodies, antibody drug conjugates, peptide conjugates, and cell therapies.
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform With new funding, Arcellx furthers its cell therapy platform intended to address new therapies in [….]
Five Cell and Gene Therapy Companies that Are Changing the Landscape of the Field